| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 35 | 2023 | 1079 | 6.340 |
Why?
|
| Head and Neck Neoplasms | 38 | 2023 | 1059 | 5.570 |
Why?
|
| Oropharyngeal Neoplasms | 15 | 2023 | 124 | 4.160 |
Why?
|
| Mouth Neoplasms | 12 | 2023 | 196 | 3.600 |
Why?
|
| Papillomavirus Infections | 16 | 2023 | 242 | 3.410 |
Why?
|
| DNA, Neoplasm | 10 | 2020 | 266 | 2.470 |
Why?
|
| Thyroid Neoplasms | 11 | 2022 | 404 | 2.260 |
Why?
|
| Mutation | 26 | 2022 | 3904 | 1.500 |
Why?
|
| Carcinoma | 8 | 2022 | 430 | 1.410 |
Why?
|
| Receptor, Notch1 | 9 | 2020 | 84 | 1.360 |
Why?
|
| Papillomaviridae | 9 | 2022 | 156 | 1.310 |
Why?
|
| Laryngectomy | 8 | 2017 | 28 | 1.180 |
Why?
|
| Biomarkers, Tumor | 12 | 2022 | 1450 | 1.170 |
Why?
|
| Neck Dissection | 5 | 2017 | 67 | 1.140 |
Why?
|
| Tongue Neoplasms | 6 | 2018 | 52 | 1.070 |
Why?
|
| Exome | 5 | 2017 | 125 | 1.060 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2020 | 370 | 1.000 |
Why?
|
| Humans | 118 | 2023 | 84425 | 0.980 |
Why?
|
| Tonsillar Neoplasms | 3 | 2019 | 7 | 0.980 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 249 | 0.950 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 309 | 0.920 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 294 | 0.920 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 57 | 0.900 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 91 | 0.900 |
Why?
|
| Saliva | 3 | 2021 | 119 | 0.890 |
Why?
|
| Alphapapillomavirus | 4 | 2021 | 48 | 0.890 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2022 | 65 | 0.890 |
Why?
|
| Betacoronavirus | 3 | 2020 | 252 | 0.800 |
Why?
|
| Middle Aged | 53 | 2022 | 24744 | 0.790 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2022 | 28 | 0.780 |
Why?
|
| Pandemics | 4 | 2020 | 704 | 0.770 |
Why?
|
| Male | 66 | 2023 | 40419 | 0.770 |
Why?
|
| Tracheotomy | 1 | 2020 | 18 | 0.760 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 158 | 0.760 |
Why?
|
| Neoplasm Staging | 14 | 2022 | 1928 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 1261 | 0.730 |
Why?
|
| Palatine Tonsil | 1 | 2019 | 30 | 0.730 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 543 | 0.720 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 46 | 0.680 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 147 | 0.670 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.660 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2015 | 144 | 0.660 |
Why?
|
| Dental Alloys | 1 | 2018 | 6 | 0.660 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 8 | 0.660 |
Why?
|
| Female | 63 | 2023 | 43872 | 0.660 |
Why?
|
| Thyroidectomy | 7 | 2022 | 169 | 0.630 |
Why?
|
| Prognosis | 17 | 2022 | 3626 | 0.630 |
Why?
|
| Life Style | 1 | 2018 | 185 | 0.600 |
Why?
|
| Liquid Biopsy | 4 | 2023 | 31 | 0.600 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 7 | 0.580 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.570 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 128 | 0.570 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 264 | 0.560 |
Why?
|
| Disability Evaluation | 1 | 2016 | 135 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1027 | 0.550 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 2249 | 0.540 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2014 | 157 | 0.540 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 322 | 0.530 |
Why?
|
| Neck | 4 | 2015 | 99 | 0.520 |
Why?
|
| Adult | 39 | 2023 | 25259 | 0.520 |
Why?
|
| Aged | 34 | 2020 | 18154 | 0.520 |
Why?
|
| Incidence | 7 | 2022 | 1559 | 0.510 |
Why?
|
| Retrospective Studies | 20 | 2022 | 8150 | 0.480 |
Why?
|
| Postoperative Complications | 8 | 2016 | 2172 | 0.480 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 135 | 0.480 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 381 | 0.480 |
Why?
|
| Carcinoma, Medullary | 1 | 2012 | 11 | 0.460 |
Why?
|
| Salvage Therapy | 3 | 2015 | 231 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2012 | 21 | 0.460 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2023 | 69 | 0.440 |
Why?
|
| Lymph Nodes | 5 | 2017 | 533 | 0.440 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2023 | 62 | 0.420 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 92 | 0.420 |
Why?
|
| F-Box Proteins | 1 | 2011 | 8 | 0.420 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 19 | 0.420 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2011 | 164 | 0.420 |
Why?
|
| Clostridium | 4 | 2005 | 21 | 0.410 |
Why?
|
| Cohort Studies | 10 | 2023 | 2717 | 0.400 |
Why?
|
| Monitoring, Intraoperative | 4 | 2018 | 108 | 0.400 |
Why?
|
| Tonsillectomy | 3 | 2023 | 29 | 0.380 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2022 | 17 | 0.380 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 319 | 0.380 |
Why?
|
| United States | 11 | 2022 | 6473 | 0.370 |
Why?
|
| ras Proteins | 2 | 2020 | 128 | 0.350 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 182 | 0.350 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 1155 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 447 | 0.340 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 6455 | 0.330 |
Why?
|
| Sex Factors | 5 | 2018 | 1041 | 0.330 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 52 | 0.330 |
Why?
|
| Parathyroid Hormone | 3 | 2018 | 212 | 0.320 |
Why?
|
| Age Factors | 5 | 2018 | 1827 | 0.310 |
Why?
|
| Pharyngectomy | 3 | 2016 | 8 | 0.310 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2018 | 41 | 0.310 |
Why?
|
| Neoplasms, Experimental | 3 | 2005 | 271 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 846 | 0.300 |
Why?
|
| Oncogenes | 2 | 2020 | 87 | 0.300 |
Why?
|
| Goiter | 2 | 2018 | 43 | 0.290 |
Why?
|
| Receptors, Notch | 3 | 2022 | 119 | 0.290 |
Why?
|
| Thyroid Gland | 3 | 2022 | 263 | 0.290 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 303 | 0.290 |
Why?
|
| Radiotherapy Dosage | 4 | 2020 | 490 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 103 | 0.290 |
Why?
|
| Risk Factors | 6 | 2021 | 5312 | 0.280 |
Why?
|
| Repressor Proteins | 3 | 2015 | 397 | 0.280 |
Why?
|
| Patient Selection | 3 | 2020 | 684 | 0.280 |
Why?
|
| Thyroid Nodule | 2 | 2016 | 47 | 0.280 |
Why?
|
| SEER Program | 2 | 2016 | 184 | 0.270 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 1204 | 0.270 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 1362 | 0.260 |
Why?
|
| ErbB Receptors | 2 | 2020 | 480 | 0.260 |
Why?
|
| DNA Mutational Analysis | 5 | 2016 | 526 | 0.260 |
Why?
|
| Risk Assessment | 7 | 2018 | 2230 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 2401 | 0.250 |
Why?
|
| Databases, Factual | 3 | 2018 | 792 | 0.250 |
Why?
|
| Hypothermia | 1 | 2003 | 26 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1196 | 0.240 |
Why?
|
| Young Adult | 8 | 2022 | 5861 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 136 | 0.230 |
Why?
|
| Ganglioneuroblastoma | 1 | 2023 | 4 | 0.230 |
Why?
|
| Brain Neoplasms | 3 | 2015 | 755 | 0.230 |
Why?
|
| DNA, Viral | 2 | 2022 | 263 | 0.230 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 17 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 42 | 0.220 |
Why?
|
| Head | 1 | 2003 | 130 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 424 | 0.220 |
Why?
|
| Oral Health | 2 | 2022 | 11 | 0.220 |
Why?
|
| Re-Irradiation | 1 | 2022 | 16 | 0.220 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 11 | 0.220 |
Why?
|
| Decision Making | 2 | 2020 | 632 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 386 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 236 | 0.210 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 181 | 0.210 |
Why?
|
| Transcriptome | 3 | 2021 | 559 | 0.210 |
Why?
|
| Cloud Computing | 1 | 2021 | 7 | 0.210 |
Why?
|
| DNA Methylation | 3 | 2015 | 607 | 0.210 |
Why?
|
| Gastric Bypass | 1 | 2023 | 109 | 0.210 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1054 | 0.210 |
Why?
|
| Smoking | 3 | 2020 | 603 | 0.210 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 479 | 0.210 |
Why?
|
| DNA Helicases | 2 | 2012 | 76 | 0.210 |
Why?
|
| Societies, Medical | 4 | 2018 | 571 | 0.200 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 14 | 0.200 |
Why?
|
| RNA, Messenger | 4 | 2016 | 1966 | 0.200 |
Why?
|
| Survival Analysis | 5 | 2018 | 1535 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2432 | 0.200 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.200 |
Why?
|
| Parathyroidectomy | 2 | 2018 | 77 | 0.200 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 53 | 0.200 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 3598 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 161 | 0.200 |
Why?
|
| Nuclear Proteins | 4 | 2012 | 688 | 0.190 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 375 | 0.190 |
Why?
|
| Bacteria | 2 | 2023 | 436 | 0.190 |
Why?
|
| Larynx, Artificial | 2 | 2011 | 2 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 13 | 0.190 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 193 | 0.190 |
Why?
|
| Oncogene Protein v-akt | 1 | 2020 | 21 | 0.190 |
Why?
|
| Obesity, Morbid | 1 | 2023 | 217 | 0.190 |
Why?
|
| User-Computer Interface | 1 | 2021 | 185 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 290 | 0.190 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 145 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 208 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1646 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 156 | 0.180 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 26 | 0.180 |
Why?
|
| Cyclin D1 | 1 | 2020 | 83 | 0.180 |
Why?
|
| Checklist | 1 | 2020 | 56 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 66 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.180 |
Why?
|
| Brain Stem Neoplasms | 1 | 2019 | 17 | 0.180 |
Why?
|
| Human papillomavirus 16 | 2 | 2016 | 38 | 0.180 |
Why?
|
| Radiation Dosage | 1 | 2020 | 223 | 0.180 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 182 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
| Point Mutation | 1 | 2019 | 246 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 366 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2022 | 7829 | 0.170 |
Why?
|
| Consensus | 2 | 2018 | 318 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 114 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 359 | 0.170 |
Why?
|
| Glossectomy | 2 | 2016 | 4 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 181 | 0.170 |
Why?
|
| beta Catenin | 1 | 2020 | 246 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2018 | 93 | 0.160 |
Why?
|
| APOBEC Deaminases | 1 | 2017 | 5 | 0.160 |
Why?
|
| Computational Biology | 1 | 2021 | 527 | 0.160 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 372 | 0.160 |
Why?
|
| Reoperation | 3 | 2016 | 585 | 0.160 |
Why?
|
| Confidence Intervals | 1 | 2018 | 229 | 0.160 |
Why?
|
| Glottis | 1 | 2017 | 12 | 0.160 |
Why?
|
| Metals | 1 | 2018 | 89 | 0.160 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 93 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 330 | 0.160 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2234 | 0.160 |
Why?
|
| Hypocalcemia | 2 | 2014 | 40 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 1651 | 0.150 |
Why?
|
| Survival Rate | 3 | 2020 | 1852 | 0.150 |
Why?
|
| Adolescent | 7 | 2022 | 8828 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 159 | 0.150 |
Why?
|
| Arabinofuranosyluracil | 2 | 2007 | 6 | 0.150 |
Why?
|
| Sclerotherapy | 1 | 2016 | 15 | 0.150 |
Why?
|
| Thymidine Kinase | 2 | 2007 | 30 | 0.150 |
Why?
|
| Vascular Malformations | 1 | 2016 | 18 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2506 | 0.150 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2016 | 9 | 0.150 |
Why?
|
| Gene Silencing | 2 | 2014 | 172 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.150 |
Why?
|
| Endoscopy | 2 | 2011 | 323 | 0.150 |
Why?
|
| Bleomycin | 1 | 2016 | 97 | 0.140 |
Why?
|
| Exons | 3 | 2015 | 447 | 0.140 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2016 | 7 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 537 | 0.140 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2015 | 34 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 30 | 0.140 |
Why?
|
| Receptor, Notch2 | 2 | 2012 | 6 | 0.140 |
Why?
|
| Time Factors | 5 | 2018 | 5179 | 0.140 |
Why?
|
| Proton Therapy | 1 | 2015 | 26 | 0.140 |
Why?
|
| Calcium | 2 | 2018 | 1132 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 3 | 2009 | 502 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 459 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2016 | 84 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 322 | 0.140 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1202 | 0.140 |
Why?
|
| North America | 2 | 2013 | 173 | 0.140 |
Why?
|
| China | 2 | 2014 | 220 | 0.140 |
Why?
|
| Biopsy | 1 | 2019 | 1144 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 207 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2017 | 223 | 0.140 |
Why?
|
| Spores, Bacterial | 2 | 2005 | 18 | 0.140 |
Why?
|
| Signal Transduction | 5 | 2022 | 3198 | 0.130 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2015 | 48 | 0.130 |
Why?
|
| Carbolines | 1 | 2015 | 8 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 169 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 8 | 0.130 |
Why?
|
| Mandible | 1 | 2016 | 118 | 0.130 |
Why?
|
| Leukoplakia, Oral | 1 | 2014 | 10 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 264 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2018 | 331 | 0.130 |
Why?
|
| Algorithms | 4 | 2016 | 1812 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 160 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 106 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 66 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 15 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2020 | 602 | 0.130 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2014 | 13 | 0.130 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 8 | 0.130 |
Why?
|
| Gene Dosage | 2 | 2013 | 207 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 293 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2014 | 174 | 0.120 |
Why?
|
| Bacterial Toxins | 2 | 2005 | 111 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 176 | 0.120 |
Why?
|
| Age Distribution | 1 | 2014 | 204 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2016 | 190 | 0.120 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 10 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 253 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 928 | 0.120 |
Why?
|
| Metagenome | 1 | 2014 | 98 | 0.120 |
Why?
|
| Enteral Nutrition | 3 | 2020 | 103 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 37 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1062 | 0.120 |
Why?
|
| Ependymoma | 1 | 2013 | 17 | 0.120 |
Why?
|
| Radiography | 1 | 2015 | 801 | 0.120 |
Why?
|
| Mutation, Missense | 2 | 2011 | 274 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2016 | 361 | 0.120 |
Why?
|
| Papanicolaou Test | 1 | 2013 | 38 | 0.110 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2012 | 49 | 0.110 |
Why?
|
| Receptor, Notch3 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2395 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2013 | 82 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 311 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2013 | 67 | 0.110 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 168 | 0.110 |
Why?
|
| Genomics | 2 | 2016 | 690 | 0.110 |
Why?
|
| Vocal Cords | 2 | 2011 | 24 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 53 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 80 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 50 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 176 | 0.110 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 4 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2011 | 30 | 0.100 |
Why?
|
| Geography | 1 | 2012 | 223 | 0.100 |
Why?
|
| Animals | 13 | 2022 | 26191 | 0.100 |
Why?
|
| Oligodendroglioma | 1 | 2011 | 44 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 254 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 41 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 854 | 0.100 |
Why?
|
| Tobacco | 1 | 2011 | 59 | 0.100 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 67 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2011 | 109 | 0.100 |
Why?
|
| Carboplatin | 2 | 2022 | 287 | 0.100 |
Why?
|
| Child | 6 | 2022 | 6763 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2013 | 249 | 0.100 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 76 | 0.100 |
Why?
|
| Mice | 10 | 2021 | 11055 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 4 | 2005 | 1041 | 0.100 |
Why?
|
| Neurons | 3 | 2009 | 1506 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2022 | 459 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 189 | 0.090 |
Why?
|
| Lipomatosis | 1 | 2010 | 8 | 0.090 |
Why?
|
| Models, Biological | 2 | 2015 | 1731 | 0.090 |
Why?
|
| Lipoma | 1 | 2010 | 24 | 0.090 |
Why?
|
| Neoplasms | 4 | 2014 | 2809 | 0.090 |
Why?
|
| Glioma | 1 | 2012 | 280 | 0.090 |
Why?
|
| MPTP Poisoning | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cisplatin | 2 | 2022 | 603 | 0.090 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 27 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 228 | 0.090 |
Why?
|
| DNA | 1 | 2015 | 1275 | 0.090 |
Why?
|
| Intestinal Neoplasms | 1 | 2010 | 55 | 0.090 |
Why?
|
| Lung | 1 | 2015 | 1134 | 0.090 |
Why?
|
| Biomarkers | 2 | 2023 | 1668 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 684 | 0.090 |
Why?
|
| Safety Management | 2 | 2020 | 56 | 0.090 |
Why?
|
| Speech, Alaryngeal | 1 | 2008 | 3 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 92 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2016 | 93 | 0.080 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 147 | 0.080 |
Why?
|
| Voice Quality | 1 | 2008 | 11 | 0.080 |
Why?
|
| Base Sequence | 1 | 2012 | 2321 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 993 | 0.080 |
Why?
|
| Robotics | 1 | 2011 | 265 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2022 | 4089 | 0.080 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.080 |
Why?
|
| Microsurgery | 1 | 2008 | 82 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2010 | 300 | 0.080 |
Why?
|
| Oral Fistula | 1 | 2007 | 2 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1128 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2007 | 14 | 0.080 |
Why?
|
| Cutaneous Fistula | 1 | 2007 | 13 | 0.080 |
Why?
|
| Laryngoscopy | 2 | 2022 | 45 | 0.080 |
Why?
|
| Contrast Media | 1 | 2012 | 1061 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 23 | 0.080 |
Why?
|
| Muscles | 1 | 2007 | 188 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 69 | 0.080 |
Why?
|
| Laser Therapy | 1 | 2008 | 140 | 0.080 |
Why?
|
| Rabbits | 2 | 2005 | 635 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2005 | 276 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2023 | 3577 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 723 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1787 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2007 | 263 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 671 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 182 | 0.070 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2005 | 5 | 0.070 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 5 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2022 | 288 | 0.070 |
Why?
|
| Huntington Disease | 1 | 2005 | 37 | 0.070 |
Why?
|
| Length of Stay | 3 | 2014 | 683 | 0.070 |
Why?
|
| Bacteriolysis | 1 | 2004 | 1 | 0.070 |
Why?
|
| Behavior | 1 | 2005 | 85 | 0.070 |
Why?
|
| Escherichia coli Infections | 1 | 2005 | 35 | 0.060 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 130 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 80 | 0.060 |
Why?
|
| Bacteria, Anaerobic | 1 | 2003 | 3 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2015 | 307 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 108 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2003 | 24 | 0.060 |
Why?
|
| Microtubules | 1 | 2004 | 117 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1755 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 459 | 0.060 |
Why?
|
| Body Temperature | 1 | 2003 | 123 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2003 | 47 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 346 | 0.060 |
Why?
|
| Pharynx | 1 | 2023 | 46 | 0.060 |
Why?
|
| Adenoidectomy | 1 | 2023 | 22 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2003 | 82 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2003 | 110 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2003 | 203 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2003 | 123 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 903 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 2004 | 120 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 430 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2022 | 11 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 92 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 49 | 0.050 |
Why?
|
| Parathyroid Glands | 1 | 2022 | 72 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 925 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 134 | 0.050 |
Why?
|
| Apoptosis | 2 | 2005 | 1669 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 271 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 353 | 0.050 |
Why?
|
| Lip | 1 | 2021 | 17 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 257 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 162 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1168 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2020 | 23 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 143 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 555 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 1503 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 243 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 276 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 268 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 28 | 0.050 |
Why?
|
| Surgical Oncology | 1 | 2020 | 26 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 123 | 0.050 |
Why?
|
| Cell Line | 4 | 2005 | 2452 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 327 | 0.050 |
Why?
|
| Age of Onset | 1 | 2020 | 306 | 0.050 |
Why?
|
| Deglutition | 1 | 2020 | 69 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 57 | 0.050 |
Why?
|
| India | 1 | 2020 | 122 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 261 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 62 | 0.050 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 234 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2003 | 766 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 742 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 11 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 21 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1366 | 0.040 |
Why?
|
| Genes, myc | 1 | 2019 | 39 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 49 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 106 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1747 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 632 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 872 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 251 | 0.040 |
Why?
|
| Lysine | 1 | 2019 | 142 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 259 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 81 | 0.040 |
Why?
|
| Hypoxia | 1 | 2003 | 628 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 102 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1181 | 0.040 |
Why?
|
| American Dental Association | 1 | 2017 | 10 | 0.040 |
Why?
|
| Evidence-Based Dentistry | 1 | 2017 | 10 | 0.040 |
Why?
|
| S-Nitrosoglutathione | 2 | 2009 | 10 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2005 | 3050 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2009 | 22 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 325 | 0.040 |
Why?
|
| Mouth | 1 | 2017 | 48 | 0.040 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 53 | 0.040 |
Why?
|
| N-Methylaspartate | 2 | 2009 | 51 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 183 | 0.040 |
Why?
|
| Indoles | 1 | 2019 | 316 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 298 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 62 | 0.040 |
Why?
|
| Germ Cells | 1 | 2017 | 116 | 0.040 |
Why?
|
| Exanthema | 1 | 2016 | 34 | 0.040 |
Why?
|
| Cetuximab | 1 | 2016 | 114 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2016 | 17 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 213 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2016 | 23 | 0.040 |
Why?
|
| Amines | 1 | 2016 | 25 | 0.040 |
Why?
|
| Maryland | 1 | 2015 | 35 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 35 | 0.040 |
Why?
|
| Protein Transport | 2 | 2009 | 408 | 0.040 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2015 | 37 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 41 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 398 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 72 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2015 | 42 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 80 | 0.030 |
Why?
|
| Transfection | 2 | 2009 | 892 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 14 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 121 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 81 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2016 | 68 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 348 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1366 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 147 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 672 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 212 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2009 | 2208 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 108 | 0.030 |
Why?
|
| Tadalafil | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2016 | 57 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 171 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 130 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 709 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 170 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 917 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 114 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 375 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 246 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 303 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1506 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 32 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 50 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 914 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 194 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 178 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 158 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 273 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 148 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3306 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.030 |
Why?
|
| Protein Binding | 2 | 2009 | 1439 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2659 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1566 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 420 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1970 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2005 | 787 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2012 | 3 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 855 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2009 | 1894 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 277 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2788 | 0.030 |
Why?
|
| Baltimore | 1 | 2011 | 36 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 1041 | 0.030 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 20 | 0.030 |
Why?
|
| Seroma | 1 | 2011 | 6 | 0.030 |
Why?
|
| Learning Curve | 1 | 2011 | 18 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 574 | 0.030 |
Why?
|
| Vocal Cord Paralysis | 1 | 2011 | 26 | 0.030 |
Why?
|
| Telomere | 1 | 2012 | 104 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 674 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 85 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 59 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2011 | 90 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 100 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 691 | 0.030 |
Why?
|
| Hematoma | 1 | 2011 | 98 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2057 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 301 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 747 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 272 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 3025 | 0.020 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2009 | 45 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 145 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 331 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 207 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 302 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2007 | 59 | 0.020 |
Why?
|
| Visual Fields | 1 | 2008 | 98 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 934 | 0.020 |
Why?
|
| Magnetics | 1 | 2007 | 41 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 542 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 36 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 118 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 534 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2008 | 189 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 346 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 3000 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 242 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2005 | 10 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 664 | 0.020 |
Why?
|
| Densitometry | 1 | 2005 | 29 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 348 | 0.020 |
Why?
|
| Escape Reaction | 1 | 2005 | 12 | 0.020 |
Why?
|
| Electron Transport | 1 | 2005 | 71 | 0.020 |
Why?
|
| Retinal Degeneration | 1 | 2005 | 28 | 0.020 |
Why?
|
| Longevity | 1 | 2005 | 46 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 673 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 242 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 86 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 256 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 123 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 81 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 265 | 0.020 |
Why?
|
| Plasmids | 1 | 2005 | 282 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2005 | 90 | 0.020 |
Why?
|
| Cysteine | 1 | 2005 | 131 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 217 | 0.020 |
Why?
|
| Spores | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2005 | 278 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 2003 | 12 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2005 | 327 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 281 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2004 | 266 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2005 | 276 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 196 | 0.020 |
Why?
|
| Necrosis | 1 | 2004 | 196 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2004 | 199 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 500 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 393 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 574 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2004 | 178 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 967 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 362 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 372 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 533 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2005 | 591 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 525 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 1519 | 0.010 |
Why?
|
| Drosophila | 1 | 2005 | 492 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1120 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 2161 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3965 | 0.010 |
Why?
|